JPRN-UMIN000000734已完成2 期
Phase II study of FOLFOX4 in patients with advanced/recurrent colorectal cancer previously treated with 5FU (OGSG 0503) - OGSG0503
OGSG0 个研究点目标入组 50 人开始时间: 2007年6月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Excluding Criteria 1. cavity fluid which should be taken out 2. with double cancer and/or multiple cancer which excludes carcinoma in situ 3. with peripheral nerve disorder 4. with infectious disease 5. under the condition of diarrhea (watery diarrhea) 6. with psychological disorder which disturb the entry to the study 7. under continuous steroids therapy 8. with other severe diseases(pulmonary fibrosis, cardiac failure, liver dysfunction, renal dysfunction, intestinal paralysis/obstruction or uncontrolled DM) 9. pregnant and/or nursing women 10. with allergic history against medicines 11. doctors' stop not to register to the study
研究者
相似试验
已完成
不适用
Phase II study of first-line treatment by FOLFOXIRI+bevacizumab in patients with RAS mutant-type metastatic colorectal cancerColorectal CancerJPRN-UMIN000015152onprofit Organization Japan Clinical Cancer Research Organization60
已完成
2 期
A phase II study of Perioperative FOLFOX4 plus Bevacizumab for initially unresectable Advanced Colorectal Cancer.colorectal cancerJPRN-UMIN000005572Japanese foundation for cancer research49
招募中
2 期
eoadjuvant FOLFIRINOXPancreatic cancer, Neoadjuvant therapyPancreatic cancerJPRN-jRCT1041220027Yamashita Tatsuya50
已完成
2 期
A Multicenter, Clinical Phase II study of FOLFOXIRI with Bevacizumab As First-line Therapy in Patients with Metastatic Colorectal Cancer.Patients with metastatic colorectal cancer.JPRN-UMIN000013797EPS Corporation65
已完成
2 期
A phase II study of FOLFIRINOX in patients with advanced biliary tract cancerBiliary tract cancerJPRN-UMIN000020801Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo35